Entrada Therapeutics (TRDA) Stock Forecast, Price Target & Predictions
TRDA Stock Forecast
Entrada Therapeutics stock forecast is as follows: an average price target of $18.00 (represents a 20.00% upside from TRDA’s last price of $15.00) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
TRDA Price Target
The average price target for Entrada Therapeutics (TRDA) is $18.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $18.00. This represents a potential 20.00% upside from TRDA's last price of $15.00.
TRDA Analyst Ratings
According to 3 Wall Street analysts, Entrada Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TRDA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Entrada Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 25, 2024 | Raghuram Selvaraju | H.C. Wainwright | $18.00 | $14.24 | 26.40% | 20.00% |
The latest Entrada Therapeutics stock forecast, released on Jun 25, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $18.00, which represents a 26.40% increase from the stock price at the time of the forecast ($14.24), and a 20.00% increase from TRDA last price ($15.00).
Entrada Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $18.00 | $18.00 |
| Last Closing Price | $15.00 | $15.00 | $15.00 |
| Upside/Downside | -100.00% | 20.00% | 20.00% |
In the current month, the average price target of Entrada Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Entrada Therapeutics's last price of $15.00. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 14, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 25, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 24, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Nov 22, 2023 | William Blair | Outperform | Outperform | Hold |
Entrada Therapeutics's last stock rating was published by Cowen & Co. on Aug 14, 2024. The company gave TRDA a "Buy" rating, the same as its previous rate.
Entrada Therapeutics Financial Forecast
Entrada Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $41.85M | $43.73M | - | $25.26M |
| Avg Forecast | $14.11M | $7.05M | $14.11M | $14.11M | $11.62M | $11.62M | $8.71M | $11.62M | $9.76M | $12.32M | $51.86M | $14.98M | $23.69M | $9.60M | $9.78M | $7.00M |
| High Forecast | $14.11M | $7.05M | $14.11M | $14.11M | $11.62M | $11.62M | $8.71M | $11.62M | $9.76M | $15.16M | $51.86M | $14.98M | $31.08M | $9.60M | $9.78M | $7.00M |
| Low Forecast | $14.11M | $7.05M | $14.11M | $14.11M | $11.62M | $11.62M | $8.71M | $11.62M | $9.76M | $9.48M | $51.86M | $14.98M | $12.01M | $9.60M | $9.78M | $7.00M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.77% | 4.56% | - | 3.61% |
Entrada Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $14.98M, with a low forecast of $14.98M, and a high forecast of $14.98M. TRDA's average Quarter revenue forecast represents a -64.21% decrease compared to the company's last Quarter revenue of $41.85M (Dec 23).
Entrada Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $5.64M | $14.01M | - | $-5.78M |
| Avg Forecast | $11.28M | $5.64M | $11.28M | $11.28M | $9.29M | $9.29M | $6.97M | $9.29M | $7.80M | $9.85M | $41.46M | $11.97M | $18.94M | $7.67M | $7.82M | $5.60M |
| High Forecast | $11.28M | $5.64M | $11.28M | $11.28M | $9.29M | $9.29M | $6.97M | $9.29M | $7.80M | $12.12M | $41.46M | $11.97M | $24.85M | $7.67M | $7.82M | $5.60M |
| Low Forecast | $11.28M | $5.64M | $11.28M | $11.28M | $9.29M | $9.29M | $6.97M | $9.29M | $7.80M | $7.58M | $41.46M | $11.97M | $9.61M | $7.67M | $7.82M | $5.60M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.30% | 1.83% | - | -1.03% |
2 analysts predict TRDA's average Quarter EBITDA for Mar 24 to be $11.97M, with a high of $11.97M and a low of $11.97M. This is 112.27% upper than Entrada Therapeutics's previous annual EBITDA (Dec 23) of $5.64M.
Entrada Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-9.54M | $35.46M | - | $-6.67M |
| Avg Forecast | $-36.95M | $-36.77M | $-32.99M | $-31.96M | $-33.61M | $-34.68M | $-32.90M | $-32.07M | $-27.98M | $-25.85M | $12.83M | $-21.09M | $-5.98M | $-26.10M | $-24.49M | $-23.12M |
| High Forecast | $-36.95M | $-36.77M | $-32.99M | $-31.96M | $-33.61M | $-34.68M | $-32.90M | $-32.07M | $-27.98M | $-18.13M | $12.83M | $-21.09M | $17.94M | $-26.10M | $-24.49M | $-23.12M |
| Low Forecast | $-36.95M | $-36.77M | $-32.99M | $-31.96M | $-33.61M | $-34.68M | $-32.90M | $-32.07M | $-27.98M | $-33.95M | $12.83M | $-21.09M | $-45.28M | $-26.10M | $-24.49M | $-23.12M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.60% | -1.36% | - | 0.29% |
Entrada Therapeutics's average Quarter net income forecast for Dec 23 is $-5.98M, with a range of $-45.28M to $17.94M. TRDA's average Quarter net income forecast represents a -116.86% decrease compared to the company's last Quarter net income of $35.46M (Sep 23).
Entrada Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $8.65M | $7.53M | - | $7.94M |
| Avg Forecast | $11.99M | $6.00M | $11.99M | $11.99M | $9.88M | $9.88M | $7.41M | $9.88M | $8.30M | $10.47M | $44.08M | $12.73M | $20.14M | $8.16M | $8.31M | $5.95M |
| High Forecast | $11.99M | $6.00M | $11.99M | $11.99M | $9.88M | $9.88M | $7.41M | $9.88M | $8.30M | $12.89M | $44.08M | $12.73M | $26.42M | $8.16M | $8.31M | $5.95M |
| Low Forecast | $11.99M | $6.00M | $11.99M | $11.99M | $9.88M | $9.88M | $7.41M | $9.88M | $8.30M | $8.06M | $44.08M | $12.73M | $10.21M | $8.16M | $8.31M | $5.95M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.43% | 0.92% | - | 1.33% |
Entrada Therapeutics's average Quarter SG&A projection for Mar 24 is $12.73M, based on 2 Wall Street analysts, with a range of $12.73M to $12.73M. The forecast indicates a 47.15% rise compared to TRDA last annual SG&A of $8.65M (Dec 23).
Entrada Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.29 | $1.07 | - | $-0.21 |
| Avg Forecast | $-1.04 | $-1.04 | $-0.93 | $-0.90 | $-0.95 | $-0.98 | $-0.93 | $-0.90 | $-0.79 | $-0.73 | $0.36 | $-0.59 | $-0.17 | $-0.73 | $-0.69 | $-0.65 |
| High Forecast | $-1.04 | $-1.04 | $-0.93 | $-0.90 | $-0.95 | $-0.98 | $-0.93 | $-0.90 | $-0.79 | $-0.51 | $0.36 | $-0.59 | $0.51 | $-0.73 | $-0.69 | $-0.65 |
| Low Forecast | $-1.04 | $-1.04 | $-0.93 | $-0.90 | $-0.95 | $-0.98 | $-0.93 | $-0.90 | $-0.79 | $-0.96 | $0.36 | $-0.59 | $-1.28 | $-0.73 | $-0.69 | $-0.65 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.72% | -1.46% | - | 0.32% |
According to 4 Wall Street analysts, Entrada Therapeutics's projected average Quarter EPS for Dec 23 is $-0.17, with a low estimate of $-1.28 and a high estimate of $0.51. This represents a -115.74% decrease compared to TRDA previous annual EPS of $1.07 (Sep 23).
Entrada Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.51 | $24.75 | 1539.07% | Buy |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| OPT | Opthea | $3.15 | $14.00 | 344.44% | Buy |
| PEPG | PepGen | $9.48 | $29.50 | 211.18% | Buy |
| VIGL | Vigil Neuroscience | $3.67 | $11.00 | 199.73% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| LRMR | Larimar Therapeutics | $7.20 | $14.50 | 101.39% | Buy |
| PHVS | Pharvaris | $20.92 | $38.50 | 84.03% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| CRNX | Crinetics Pharmaceuticals | $53.80 | $70.14 | 30.37% | Buy |
| IRON | Disc Medicine | $47.79 | $61.80 | 29.32% | Buy |
| TRDA | Entrada Therapeutics | $15.00 | $18.00 | 20.00% | Buy |
| THRD | Third Harmonic Bio | $13.57 | $16.15 | 19.01% | Buy |
| TYRA | Tyra Biosciences | $21.24 | $25.00 | 17.70% | Buy |
| CNTA | Centessa Pharmaceuticals | $16.99 | $19.50 | 14.77% | Buy |
TRDA Forecast FAQ
Is Entrada Therapeutics a good buy?
Yes, according to 3 Wall Street analysts, Entrada Therapeutics (TRDA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of TRDA's total ratings.
What is TRDA's price target?
Entrada Therapeutics (TRDA) average price target is $18 with a range of $18 to $18, implying a 20.00% from its last price of $15. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Entrada Therapeutics stock go up soon?
According to Wall Street analysts' prediction for TRDA stock, the company can go up by 20.00% (from the last price of $15 to the average price target of $18), up by 20.00% based on the highest stock price target, and up by 20.00% based on the lowest stock price target.
Can Entrada Therapeutics stock reach $20?
TRDA's average twelve months analyst stock price target of $18 does not support the claim that Entrada Therapeutics can reach $20 in the near future.
What are Entrada Therapeutics's analysts' financial forecasts?
Entrada Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $43.57M (high $43.57M, low $43.57M), average EBITDA is $34.83M (high $34.83M, low $34.83M), average net income is $-133M (high $-133M, low $-133M), average SG&A $37.04M (high $37.04M, low $37.04M), and average EPS is $-3.753 (high $-3.753, low $-3.753). TRDA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $49.37M (high $49.37M, low $49.37M), average EBITDA is $39.47M (high $39.47M, low $39.47M), average net income is $-139M (high $-139M, low $-139M), average SG&A $41.97M (high $41.97M, low $41.97M), and average EPS is $-3.906 (high $-3.906, low $-3.906).
Did the TRDA's actual financial results beat the analysts' financial forecasts?
Based on Entrada Therapeutics's last annual report (Dec 2023), the company's revenue was $129.01M, beating the average analysts forecast of $50.06M by 157.71%. Apple's EBITDA was $-3.162M, missing the average prediction of $40.02M by -107.90%. The company's net income was $-6.685M, missing the average estimation of $-79.692M by -91.61%. Apple's SG&A was $32.29M, missing the average forecast of $42.56M by -24.12%. Lastly, the company's EPS was $-0.0002, missing the average prediction of $-2.244 by -99.99%. In terms of the last quarterly report (Dec 2023), Entrada Therapeutics's revenue was $41.85M, beating the average analysts' forecast of $23.69M by 76.66%. The company's EBITDA was $5.64M, missing the average prediction of $18.94M by -70.21%. Entrada Therapeutics's net income was $-9.544M, beating the average estimation of $-5.98M by 59.60%. The company's SG&A was $8.65M, missing the average forecast of $20.14M by -57.03%. Lastly, the company's EPS was $-0.29, beating the average prediction of $-0.168 by 72.19%